REG - CRISM Therapeutics - Positive Preclinical Data in Prostate Cancer

CRISM TherapeuticsAnnouncement

14/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251014:nRSN1888Da&default-theme=true

RNS Number : 1888D  CRISM Therapeutics Corporation  14 October 2025

The information contained within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulation (EU) No.
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act
2018. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

 

 

 

 

14 October 2025

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

Positive Preclinical Data in Prostate Cancer and Prestigious Collaborative
Doctoral Award

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery
company focused on the localised and sustained delivery of chemotherapy drugs,
today is pleased to announce significant preclinical findings and a new
research collaboration that mark key milestones in the development of its
innovative ChemoSeed® platform in prostate cancer.

Prostate cancer, the most prevalent cancer in men, is the second programme in
CRISM's pipeline of product opportunities using the implantable ChemoSeed drug
delivery platform. The Company's most advanced programme, irinotecan-ChemoSeed
in glioblastoma, remains on track for the first patients to be dosed in an
open label Phase 2 clinical trial in early 2026.

In vitro studies conducted by CRISM Therapeutics have demonstrated that the
sustained administration of docetaxel to prostate cancer cell lines is
significantly more effective than the intermittent dosing schedules currently
used in the standard of care.

Sustained administration killed 72% of the prostate cancer cells compared with
65% with intermittent dosing.  Furthermore, the concentration of docetaxel
needed to inhibit 50% (IC(50)) of prostate cancer cells from growing was 3.5nM
for sustained administration compared with 9.8nM for intermittent dosing.
The lower the IC(50), the more potent the treatment.  Finally, at lower doses
sustained administration of docetaxel resulted in continued reduction of
prostate cancer cells for 12 days, whereas with intermittent dosing there was
less reduction in the prostate cancer cells and the cells started to regrow by
day 9.

These findings strongly support the hypothesis that sustained, localised
delivery of chemotherapy, enabled by CRISM's proprietary ChemoSeed drug
delivery platform, could substantially enhance the efficacy of docetaxel, a
generic chemotherapy drug, in the treatment of prostate cancer.  Furthermore,
with ChemoSeed this increase in efficacy could be achieved with lower amounts
of docetaxel being given to the patient reducing the unwanted side effects
typically seen with this drug.

In addition, CRISM has successfully formulated docetaxel within the ChemoSeed
platform, achieving sustained drug release over a period of at least 28 days.
This major technical milestone confirms the feasibility of using ChemoSeed for
prolonged, controlled delivery of docetaxel directly into prostate tumours,
addressing a major limitation of current systemic chemotherapy approaches.

Further strengthening its R&D capabilities, CRISM Therapeutics is proud to
announce it has been awarded a prestigious Department for the Economy ("DfE")
Collaborative Doctoral Partnership ("CDP") studentship in collaboration with
Ulster University. This partnership will support the ongoing development of
docetaxel-ChemoSeed and explore its application in the personalised treatment
of prostate cancer, including potential patient-specific dosing strategies and
tumour-targeting delivery models.  The DfE will cover the university tuition
fees and provide a maintenance stipend to support the doctoral candidate's
living expenses.

Andrew Webb, Chief Executive Officer of CRISM Therapeutics, commented:

"These developments represent a major step forward in our mission to improve
outcomes for prostate cancer patients by leveraging our ChemoSeed drug
delivery platform. The data clearly suggest that delivering chemotherapy
locally and continuously, rather than intermittently and systemically, could
provide a much-needed improvement in therapeutic efficacy. Our partnership
with Ulster University will further accelerate our progress and help bring
this innovative treatment to patients faster. We welcome discussions with
potential partners and collaborators as we build momentum towards
first-in-human clinical trials."

 

-Ends-

 

 

 

 

Enquiries:

 

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Burson Buchanan
 Andrew Webb, CEO                Richard Morrison                  Mark Court / Jamie Hooper

 Chris McConville, CSO           Vadim Alexandre                   CRISM@buchanancomms.co.uk

                                 Adam Cowl
 via Burson Buchanan             +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

About CRISM Therapeutics Corporation

 

CRISM Therapeutics Corporation has developed an innovative drug delivery
technology to improve the clinical performance of cancer treatments for solid
tumours through the local delivery of chemotherapy drugs.

 

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or
the resection margin following the removal of a tumour. This directs that
therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of treating
glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the
blood brain barrier, which prevents other treatments from being able to reach
the tumour and be effective.

 

CRISM will initiate its registration-grade Phase 2 clinical trial of
irinotecan-ChemoSeed™ in patients with surgically resectable glioblastoma in
Q1 2026.

 

For more information please visit: https://www.crismtherapeutics.com/
(https://www.crismtherapeutics.com/)

 

The Company's LEI is 213800XFW6MKVCHHPW88.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPKNBNFBDDOKD



            Copyright 2019 Regulatory News Service, all rights reserved